tirzepatide and parkinson's disease GLP-1 drug may help with disease, study reports Targeting Metabolic Dysfunction in Parkinson's

The regulation of calcium ion flow and neurotransmitter release is tightly controlled by voltage-gated ion channels and various signaling molecules, ensuring rapid and coordinated muscle responses

One is a GLP-1 agonist (Semaglutide) working through the incretin system, whereas the other (Cagrilintide) is an amylin analog working through the satiety system

Retrieved November 29, 2017

Turns out, there are ways to optimize these microscopic MVPs

The findings challenge a longstanding clinical gap: despite type 2 diabetes being recognized as a cardiovascular risk equivalent for decades, intensive lipid-lowering has historically been reserved for patients with a prior heart attack or stroke